An Open-label, Phase II, Single-arm Study of Everolimus in Combination With Letrozole in the Treatment of Postmenopausal Women With Estrogen Receptor Positive HER2 Negative Metastatic or Locally Advanced Breast Cancer
Latest Information Update: 05 May 2023
At a glance
- Drugs Dexamethasone (Primary) ; Everolimus (Primary) ; Letrozole (Primary) ; Exemestane
- Indications Advanced breast cancer
- Focus Therapeutic Use
- Acronyms BOLERO-4
- Sponsors Novare Pharmaceuticals; Novartis
- 09 Mar 2021 Status changed from active, no longer recruiting to completed.
- 13 Jan 2021 Planned End Date changed from 30 Sep 2020 to 29 Jan 2021.
- 23 Jun 2020 Planned End Date changed from 4 Jun 2020 to 30 Sep 2020.